[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

611.P1.69 Leukemias - Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis Poster II

Oral and Poster Abstracts
Poster Session
Sunday, December 6, 2009: 6:00 PM-8:00 PM
Hall E (Ernest N. Morial Convention Center)
Automated and Rapid Detection of BCR-ABL Kinase Domain Mutations in IM Resistant Patients with Ph+ Leukemias

Ruriko Tanaka, MMSc1*, Shinya Kimura, MD, PhD2*, Toshiya Hosomi3*, Mitsuharu Hirai3*, Rina Nagao1, Asumi Yokota, MMSc1*, Yuri Kamitsuji, MD, PhD4*, Eri Kawata, MD, PhD5*, Hisayuki Yao, MD6*, Kazuki Sakai, MD1*, Hideyo Hirai, MD, PhD1*, Eishi Ashihara, MD, PhD1, Souichi Adachi, MD, PhD7* and Taira Maekawa, MD, PhD1*

1Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
2hematology, Respiratory Diseases, and Oncology, Saga University, Saga, Japan
3ARKRAY, Inc., Kyoto
4Department of Hematology, Matsushita Memorial Hospital, Moriguchi City, OSAKA, Japan
5Internal Medicine, Kyoto Second Red Cross Hospital, Kyoto, Japan
6Transfusion & Cell Therapy, Kyoto University Hospital, Kyoto, Japan
7Dept. of Pediatrics, Kyoto University Graduate School of Medicine

Relapsed Childhood High Hyperdiploid Acute Lymphoblastic Leukemia: Genome-Wide Screening Reveals the Presence of Preleukemic Ancestral Clones and the Secondary Nature of Microdeletions and RTK-RAS Mutations

Josef Davidsson, PhD1*, Kajsa Paulsson, PhD1, David Lindgren, PhD1*, Henrik Lilljebjörn, MS1*, Tracy Chaplin, MS2*, Erik Forestier, MD, PhD3*, Mette K Andersen, MD, PhD4*, Ann Nordgren, MD, PhD5*, Richard Rosenquist, MD, PhD6, Thoas Fioretos, MD, PhD1*, Bryan D Young, PhD2* and Bertil Johansson, MD, PhD1

1Department of Clinical Genetics, Lund University Hospital, Lund, Sweden
2Medical Oncology Unit, Cancer Research UK, London, United Kingdom
3Department of Pediatrics, Umeå University Hospital, Umeå, Sweden
4Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark
5Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
6Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden

Twist-1 Expression Represents a Novel Prognostic Factor in Chronic Myelogenous Leukemia

Franck Emmanuel Nicolini, MD, PhD1, Erika Cosset, MSc2*, Ghassan Hamdan, MSc2*, Sandrine Jeanpierre, BSc2*, Charles Dumontet, MD, PhD3, Thibault Voeltzel, PhD2*, Alain Puisieux, PharmD, PhD2* and Véronique Maguer-Satta, PhD2*

1Hematology, Hopital Edouard Herriot, Lyon, France
2Unité INSERM U590, Centre Léon Bérard, Lyon
3Unité INSERM U590, Centre Léon Berard, Lyon, France

Expression of WT1, Survivin, and TERT genes in Acute Myeloid Leukemia: Important Clinical Prognostic Indicators Envisioning Triple Immunotherapeutic Targets

Heeje Kim1, Hee-Baeg Choi2*, Tai-Hyang Lee1*, Hyun-Jung Sohn2*, Tai-Gyu Kim2* and Woo-Sung Min3*

1Hematology, Internal Medicine, Catholic BMT Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea
2Catholic Hematopoietic Stem Cell Bank, Dept. of Microbiology, The Catholic University of Korea College of Medicine, Seoul, South Korea
3Hematology, Catholic BMT Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea

Trisomy 8 in the Light of Recent Cytogenetic Classification Advances. A Study From the French Acute Myeloid Leukemia IntergroupClinically Relevant Abstract

Nicolas Boissel1*, Christine Terré2*, Pascale Cornillet-Lefebvre3*, Odile Maarek4*, Eric Lippert5*, Isabelle Tigaud6*, Nicole Dastugue7*, Claude Preudhomme8, Norbert Ifrah, MD9, Hervé Dombret10 and Isabelle Luquet, MD, PhD11*

1Hematology Department, Hopital Saint Louis, Paris, France
2Hôpital Mignot, Versailles, France
3CHU de Reims, Laboratoire d'Hématologie, Reims, France
4Hôpital Saint-Louis, AP-HP, Paris, France
5Laboratoire d'Hématologie, Centre Hospitalier Universitaire, Bordeaux, France
6Laboratoire de Cytogénétique, Centre Hospitalier Lyon Sud, Lyon, France
7Laboratoire d'Hématologie, Hôpital Purpan, Toulouse, France
8Centre de Biologie Pathologie PM Degand; INSERM U837, Lille, France
9Service des Maladies du Sang, CHU d'Angers, Angers, France
10Hopital Saint Louis AP-HP, Paris, France
11Laboratoire central d'Hématologie, Hôpital Robert Debré, Reims, France

CD33/CD10 Ratios in the Blast Region Evaluated by Flow Cytometry Predicts the Response of Chronic Myelogeneous Leukemia to ImatinibClinically Relevant Abstract

Satoko Oka1* and Masaki Mori2

1Department of Medicine, Jichi Medical University, Shimotsuke, Japan
2Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsukeshi, Japan

Acute Leukaemias with TEL/ABL Fusion: a Subgroup with Poor Prognosis and Prenatal Origin

Jan Zuna1, Marketa Zaliova1*, Katerina Muzikova1*, Claus Meyer2*, Libuse Lizcova3*, Zuzana Zemanova3*, Jana Brezinova4*, Felix Votava5*, Rolf Marschalek2*, Jan Stary1* and Jan Trka1

1CLIP, Department of Pediatric Hematology and Oncology, Charles University Prague, 2nd Faculty of Medicine, Prague, Czech Republic
2Institute of Pharmaceutical Biology, ZAFES, Diagnostic Center of Acute Leukemia, Goethe-University of Frankfurt, Biocenter, Frankfurt/M, Germany
3Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and Charles University Prague, 1st Faculty of Medicine, Prague, Czech Republic
4Institute of Hematology and Blood Transfusion, Prague, Czech Republic
5Department of Pediatrics, Charles University Prague, 3rd Faculty of Medicine, Prague, Czech Republic

Selective FLT3 Inhibitor FI-700 Neutralizes Mcl-1 and Enhances p53-Mediated Apoptosis in Acute Myeloid Leukemia (AML) Cells with Activating Mutations of FLT3 Via Mcl-1/Noxa Axis

Kensuke Kojima, MD, PhD1, Marina Konopleva, MD, PhD2, Twee Tsao3*, Michael Andreeff, MD, PhD3, Hiroshi Ishida4*, Yukimasa Shiotsu, PhD4, Linhua Jin, PhD5*, Yoko Tabe, MD, PhD5* and Hideki Nakakuma, MD, PhD1

1Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
2Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3Stem Cell Transplantation & Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
4Research Division, Kyowa Hakko Kirin Co., Ltd, Shizuoka, Japan
5Clinical Laboratory Medicine, Juntendo University School of Medicine, Tokyo, Japan

Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy:  A Report From the Children’s Oncology Group (COG)

Nyla A. Heerema, PhD1, Andrew J. Carroll, PhD2, Michael J. Borowitz, MD, PhD3, Meenakshi Devidas, PhD4*, Eric C. Larson, M.D.5*, Mignon Loh, MD6, Leonard A. Mattano Jr., MD7, Kelly Maloney, MD8, Elizabeth Raetz, MD9, Brent Wood, MD, PhD10, Naomi J. Winick, MD11, Stephen P Hunger, MD12 and William L. Carroll, MD13

1Department of Pathology, The Ohio State University, Columbus, OH
2Department of Genetics, University of Alabama at Birmingham, Birmingham, AL
3Hematologic Pathology, Johns Hopkins University, Baltimore, MD
4Children's Oncology Group, Gainsville, FL
5Pediatric Oncology, Maine Children's Cancer Program, Scarborough, ME
6Department of Pediatrics, UCSF School of Medicine, San Francisco, CA
7Pediatric Hematology/Oncology, MSU Kalamazoo Center for Medical Studies, Kalamazoo, MI
8The Childrens' Hospital, Aurora, CO
9Pediatric Hematology/Oncology, New York University Medical Center, New York, NY
10Seattle Cancer Care Alliance, Seattle, WA
11University of Texas Southwestern Medical Center, Dallas, TX
12Pediatric Heme/Onc/BMT, University of Colorado College of Medicine, Aurora, CO
13New York University Cancer Institute, New York, NY

FISH Reveals Abnormalities of Unsuspected Regions in Chromosomally Normal De Novo Myelodysplastic Syndromes (MDS)

Paolo Bernasconi, MD1, Irene Dambruoso1*, Marina Boni1*, Paola Maria Cavigliano2*, Ilaria Giardini2*, Barbara Rocca2*, Rita Zappatore2*, Celeste Calvello2*, Marilena Caresana2* and Mario Lazzarino3*

1Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
2Division of Hematology Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

Chromosomal Abnormalities and TET2 Involvement in Therapy-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemias (t-AML)

Paolo Bernasconi, MD1, Irene Dambruoso2*, Marina Boni2*, Cesare Astori3*, Paola Maria Cavigliano2*, Patrizia Zappasodi2*, Ilaria Giardini2*, Barbara Rocca2*, Rita Zappatore2*, Celeste Calvello2*, Marilena Caresana2*, Ercole Brusamolino4*, Carlo Castagnola5* and Mario Lazzarino6*

1Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
2Division of Hematology Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, Pavia, Italy
4Clinica Ematologica, Università Policlinico San Matteo, Pavia, Italy
5Policlinico San Matteo IRCCS, Pavia, Italy
6Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

The Presence of Minimal Residual Disease Pre- and Post-Transplant Is Predictive of Outcome in Recipients of Allogeneic Transplantation for Acute Myeloid Leukaemia

Fiona L Dignan1*, Chloe Anthias1*, Mark E Ethell1*, Ricardo Morilla2*, Alison Morilla2*, Faith E Davies, MD3, Gareth J Morgan4*, Michael N Potter1 and Bronwen E Shaw1*

1Section of Haemato-oncology, Royal Marsden Hospital, Sutton, United Kingdom
2Institute of Cancer Research, Sutton, United Kingdom
3Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom
4Institute of Cancer Research, London, United Kingdom

Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) StudyClinically Relevant Abstract

Krzysztof Mrózek, MD, PhD1*, Kelsi B. Holland, MS1*, Mark J. Pettenati, PhD2*, Kati Maharry, MAS1*, Guido Marcucci, MD1, Maria R. Baer, MD3, Jonathan E. Kolitz, MD4, Dean Margeson, MAS1*, Colin G. Edwards, PhD1*, Andrew J. Carroll, PhD5, Richard A. Larson, MD6 and Clara D. Bloomfield, MD1

1The Ohio State University Comprehensive Cancer Center, Columbus, OH
2Genetics, Wake Forest University, Winston-Salem, NC
3University of Maryland, Baltimore, MD
4Medicine, North Shore University Hospital, Lake Success, NY
5Department of Genetics, University of Alabama at Birmingham, Birmingham, AL
6University of Chicago, Chicago, IL

The AML Prognostic Marker, AF1q, Is Directly Regulated by MiR-29b

Yin Xiong, PhD1, Zejuan Li, MD, PhD2, Aik Choon Tan1*, Judson Bemis1*, Xiuyan Xie3*, Kevin D. Bunting, PhD3, Jianjun Chen2, Lynne Bemis, Ph.D1* and William Tse, M.D.1*

1University of Colorado Cancer Center, University of Colorado Denver, Aurora, CO
2Dept. of Medicine, The University of Chicago, Chicago, IL
3Medicine, Case Western Reserve Univ., Cleveland, OH

CREB Deficiency: A Potential Critical Factor for Selective GM-CSF Hypersensitivity in Juvenile Myelomonocytic Leukemia

Y. Lucy Liu, MD, PhD1, Priyangi A Malaviarachchi, BS1*, Shelly Y. Lensing, MS2*, Robert P. Castleberry, MD3* and Peter Dean Emanuel, MD1

1Winthrop P. Rockefeller Cancer Institute & College of Medicine, Internal Medicine-Hematology/Oncology, Univ. of Arkansas for Medical Sciences, Little Rock, AR
2College of Medicine, Dept. of Biostatistics, Univ. of Arkansas for Medical Sciences, Little Rock, AR
3Children's Hospital, Birmingham, AL

Expression of Annexin 2 in Pediatric B-Acute Lymphoblastic Leukemia: A Marker of Aggressiveness and A Potential Therapeutic Target

Manuela Tumino, M.D.1*, Benedetta Accordi, Ph.D.2*, Manuela Sciro, B.D.2*, Gloria Milani2*, Federica Tognazzo2*, Marco Giordan2*, Truus Te Kronnie, Ph.D.2*, Giuseppe Basso, M.D., Ph.D., Full, Professor, in, Pediatrics2* and Luca Lo Nigro, M.D., Ph.D.1

1Center of Pediatric Hematology Oncology, University of Catania, Catania, Italy
2Department of Pediatrics, University of Padova, Padova, Italy

Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy:  Results of the Children’s Oncology Group (COG) Study AALL0031

Andrew J. Carroll, PhD1, Nyla A. Heerema, PhD2, Meenakshi Devidas, PhD3*, W. Paul Bowman4*, Chenguang Wang5*, Michael Trigg, MD6, Bruce Camitta, MD7, Paul S. Gaynon, MD8, Naomi J. Winick, MD9, Stephen P Hunger, MD10, William L. Carroll, MD11 and Kirk R. Schultz, MD12

1Department of Genetics, University of Alabama at Birmingham, Birmingham, AL
2Ohio State University, Columbus, OH
3Department of Epidemiology & Health Policy Research, Children's Oncology Group & University of Florida College of Medicine, Gainesville, FL
4Hematology-Oncology, Cook Childrens Medical Center, Fort Worth, TX
5Children's Oncology Group, Gainesville, FL
6Merck & Co. Inc, North Wales, PA
7Medical College of Wisc., Milwaukee, WI
8Childrens Hosp. of Los Angeles, Los Angeles, CA
9University of Texas Southwestern Medical Center, Dallas, TX
10Pediatric Heme/Onc/BMT, University of Colorado College of Medicine, Aurora, CO
11New York University Cancer Institute, New York, NY
12B.C. Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada

Sensitivity of a Homozygous c-Cbl Mutant AML Cell Line (JPM11) to Tyrosine Kinase Inhibitors, Implications for Potential Targeted Molecular Therapy

Hideki Makishima, MD, PhD1, Yuka Sugimoto, MD, PhD1, Hadrian Szpurka, PhD1*, Courtney Prince1*, Michael Clemente1*, Hideki Muramatsu, MD2*, Andrew E. Schade, MD, PhD3 and Jaroslaw P. Maciejewski, MD, PhD1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
3Clinical Pathology, Cleveland Clinic, Cleveland, OH

SNP-Array Profiling Identifies Complex Aberrations and Candidate Genes in Myeloproliferative Neoplasms with Leukemic TransformationClinically Relevant Abstract

Frank Stegelmann1*, Martin Griesshammer2*, Karlheinz Holzmann3*, Frank G Rücker4*, Carmen Blersch4*, Susanne Kuhn4*, Stefanie Schauer4*, Hartmut Dohner4 and Konstanze Dohner4*

1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
2Hematology and Oncology, Johannes Wesling Clinic Minden, Minden, Germany
3Chip Facility/ZKF, University of Ulm, Ulm, Germany
4Internal Medicine III, University of Ulm, Ulm, Germany

Incidence and Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial

M. G Aslanyan1*, S. M.C. Langemeijer1*, D. Cilloni2, G. Saglio2, JP Marie3, R. Tang3*, B. Labar4, R. Zadro4*, D. Batinic4*, S. Amadori5, F. Lo Coco5*, T. Scheele1*, L. Kroeze1*, M. Massop1*, P. van Hoogen1*, E. Stevens1*, P. Muus1*, S. Suciu6, L. Baila6*, E. W.A. Marijt7*, R. Willemze7*, T. de Witte1*, B. van der Reijden1 and J. H. Jansen1

1Dept Hematology and Laboratory for Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
2Dept Hematology and Clinical and Biological Sciences, University of Turin, S Luigi Hospital, Turin, Italy
3Hematologie et Oncologie Medicale, Hopital Hotel-Dieu, Paris, France
4Dept Hematology and Clinical Institute of Laboratory Diagnosis, University School of Medicine, Zagreb, Croatia
5Dept of Hematology, Tor Vergata University Hospital, Rome, Italy
6EORTC Headquarters, Brussels, Belgium
7Department of Hematology, Leiden University Medical Center, Leiden, Netherlands

Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia

Kasiani C. Myers, MD1, Robert B. Gerbing, MS2*, Todd A. Alonzo, PhD3, Christine L Phillips, MD1, Alan S. Gamis, MD4, Gretchen A. Radloff5*, John Perentesis5 and Stella M. Davies, MBBS, PhD1

1Cincinnati Children's Hospital Medical Center, Cincinnati, OH
2Children's Oncology Group, Arcadia, CA
3Keck School of Medicine, University of Southern California, Arcadia, CA
4Division of Hematology/Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO
5Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML)Clinically Relevant Abstract

Marta Pratcorona1*, Montserrat Torrebadell2*, Neus Villamor2, Maria Rozman2*, Mireia Camós3*, Ana Carrió2*, Dolors Costa2*, Marina Díaz Beyá1*, Emili Montserrat1 and Jordi Esteve1

1Institute of Hematology and Oncology, Department of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
2Hematopathology Unit, Hospital Clinic, Barcelona, Spain
3Laboratory of Hematology, Hospital San Joan de Déu, Esplugues de Llobregat, Spain

Very Early/Early Relapses of ALL Show Unexpected Changes of Clonal Markers and High Heterogeneity in Initial and Relapse Treatment Response: ALL-BFM 2000 and ALL-REZ BFM 96/2002 Clinically Relevant Abstract

Cornelia Eckert1*, Rolf Koehler2*, Thomas Flohr2*, Nikola Hagedorn1*, Anja Moericke3*, Martin Stanulla3*, Renate Kirschner-Schwabe1*, Gunnar Cario3*, Arend von Stackelberg1*, Claus R Bartram2*, Guenter Henze1*, Martin Schrappe3 and Andre Schrauder3*

1Department of Pediatric Oncology/Hematology, Charité - Medical University, Berlin, Germany
2Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany
3Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany

Gene Expression Analysis of Independent Data Sets Identifies HBG1 to Be Associated with Outcome in Cytogenetically Normal AML

Lars Bullinger, MD1, Thomas Hielscher2*, Klaus H. Metzeler, MD3*, Ursula Botzenhardt4*, Sabrina Heinrich4*, Jürgen Krauter5*, Richard F. Schlenk, MD4*, Christian Buske, MD1*, Konstanze Döhner, MD4*, Axel Benner6*, Arnold Ganser, MD5 and Hartmut Döhner, MD1

1University of Ulm, Ulm, Germany
2GMMG and University of Heidelberg, Heidelberg, Germany
3Dept. of Internal Medicine III, University Hospital Großhadern, Ludwig-Maximilians-Universität, München, Germany
4Internal Medicine III, University of Ulm, Ulm, Germany
5Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
6Biostatistics, DKFZ, Heidelberg, Germany

RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group

Matthew A. Kutny, MD1, Todd A. Alonzo, PhD2, Robert B. Gerbing, MA3*, Kristen Miller, BS1*, Phoenix Ho, MD1*, Nyla A. Heerema, PhD4, Beverly Lange, MD5, Alan S. Gamis, MD6 and Soheil Meshinchi, MD, PhD1

1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2Keck School of Medicine, University of Southern California, Arcadia, CA
3Children's Oncology Group, Arcadia, CA
4Ohio State University, Columbus, OH
5Oncology, Children's Hosp. of Philadelphia, Philadelphia, PA
6Division of Hematology/Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO

MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib FailureClinically Relevant Abstract

Mridul Agrawal1*, Philipp Erben, MD2*, Benjamin Hanfstein3*, Hannah Daikeler, MD1*, Juliana Popa, MD1*, Thomas Schenk, MD4*, Armin Leitner, MD1*, Richard C. Woodman, MD5, Andreas Hochhaus, MD4 and Martin C Müller, MD1*

1III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
2III. Medizinische Klinik, Universitaetsmedizin Mannheim, 68167 Mannheim, Germany
3III. Medizinische Klinik, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
4Universitätsklinikum Jena, Jena, Germany
5Novartis Pharmaceuticals Corporation, East Hanover, NJ

Harmonization of Molecular Monitoring of CML Therapy in Europe – Perspective of Widespread Competence in BCR-ABL Quantification

Martin C Müller, MD1*, Nicholas C.P. Cross2, Philipp Erben, MD3*, Thomas Schenk, MD4*, Thomas Ernst, MD2*, Rudiger Hehlmann, MD3*, Susan Branford, PhD5, Giuseppe Saglio6*, Andreas Hochhaus, MD4 and for the EUTOS Molecular Monitoring Group3*

1III. Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany
2Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom
3III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
4Universitätsklinikum Jena, Jena, Germany
5Department of Molecular Pathology, SA Pathology, Adelaide, Australia
6Department of Clinical and Biological Sciences, University of Turin and San Luigi Hospital, Orbassano, Italy

The Predictive Value of TP53 FISH Analysis for Treatment Response and Survival in Cytogenetic Subgroups of AML PatientsClinically Relevant Abstract

Sigal Tavor, MD1, Rachel Rothman, PhD2*, Tamar Golan, PhD2*, Nadia Voskoboinik, PhD2*, Ruth Shomrat, PhD2*, Avi Orr-Urtreger, MD, PhD2* and Elizabeth Naparstek, MD1

1Hematology and Bone marrow transplantation, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
2Institute of Genetics, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin (NPM1)Clinically Relevant Abstract

Torsten Haferlach, MD1, Katja Macijewski1*, Tamara Weiss1*, Ulrike Bacher, MD2*, Susanne Schnittger, PhD1, Wolfgang Kern, MD1, Alexander Kohlmann, PhD1, Hans-Ulrich Klein3*, Marco Vignetti4*, Alfonso Piciocchi5*, Paola Fazi6*, Maria Paola Martelli7*, Stefano Aldo Pileri8*, Miriam Miesner1*, Antonella Santucci9*, Teresa Marafioti, MD10*, Claudia Haferlach, MD1, Franco Mandelli, MD11* and Brunangelo Falini, MD7*

1MLL Munich Leukemia Laboratory, Munich, Germany
2Interdisciplinary Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany
3Department of Medical Informatics and Biomathematics, University of Münster, Münster, Germany
4Division of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy
5Gimema Data Center, Rome, Italy
6Division of Hematology, Department of Cellular Biotechonologies and Hematology, “La Sapienza” University, Rome, Italy
7Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
8Department of Hematology/Oncology, University of Bologna, Bologna, Italy
9University of Perugia, Institute of Hematology
10Nuffield Department of Clinical Laboratory Sciences, Oxford
11Universita 'La Sapienza', Rome, Italy

Development of a Novel Treatment Strategy Targeting JAK2 in Acute Myelogenous Leukemia

Shinsuke Kojima1*, Takayuki Ikezoe, MD, PhD2, Jing Yang3*, Chie Nshioka4*, Asako Takeuchi5*, Mayuka Isaka2*, Mutsuo Furihata6* and Akihito Yokoyama7*

1Hematology and Respiratory meddicine, Kochi University, Nankoku, Japan
2Hem. & Respiratory Med., Kochi University, Nankoku, Japan
3Hematology and Respiratory medicine, Kochi university, Oko-cho, Japan
4Hematology and Respiratory meddicine, Kochi university, Nankoku
5Kohci University, Nankoku, Japan
6Pathology, Kochi University, Nankoku, Japan
7Hematology and Respiratory Medicine, Kochi University, Nankoku, Japan

High Frequencies of Simultaneous FLT3-ITD, WT1, and KIT mutations in NUP98-Related Hematologic Malignancies

Takeshi Taketani1, Tomohiko Taki2, Seiji Fukuda, MD, PhD3, Chie Onishi, MD4*, Mariko Abe, MD3*, Seiji Yamaguchi, MD3* and Yasuhide Hayashi5

1Division of Blood Transfusion, Shimane University Hospital, Shimane, Japan
2Department of Molecular Laboratory Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan
3Dept. of Pediatrics, Shimane Univ., Izumo, Japan
4Depratment of Hematology, Shimane University School of Medicine, Izumo, Japan
5Hematology/Oncology, Gunma Children's Medical Center, Shibukawa, Japan

Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment TrialsClinically Relevant Abstract

Sabine Kayser1*, Konstanze Doehner1*, Juergen Krauter2*, Heinz A. Horst3*, Marie von Lilienfeld-Toal4*, Ulrich Germing5*, Katharina Goetze6*, Michael Pfreundschuh7, Walter Fiedler, MD8, Daniela Spaeth1*, Silja Groner1*, Brigitte Schlegelberger9, Gudrun Goehring10*, Arnold Ganser, MD11, Hartmut Doehner1* and Richard F. Schlenk1

1Internal Medicine III, University Hospital of Ulm, Ulm, Germany
2Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
3Internal Medicine II, University Hospital Schleswig-Holstein Kiel, Kiel, Germany
4Internal Medicine III, University Hospital of Bonn, Bonn, Germany
5Hematology/Oncology, Heinrich-Heine-University, Duesseldorf, Germany
6Internal Medicine III, Technical University of Munich, Munich, Germany
7Internal Medicine I, University of Homburg, Homburg, Germany
8Department of Hematology and Oncology with sections Pneumonology and Bone Marrow Transplantation, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
9Inst. of Cell & Molecular Pathology, Hannover Medical School, Hannover, Germany
10Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Medizinische Hochschule Hannover, Hannover, Germany
11Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Gene Expression Changes in Bone Marrow of MDS Patients with Del(5q) During Lenalidomide Treatment

Esther Natalie Oliva, MD1, Maria Cuzzola, Biologist2*, Roberto Latagliata, MD3*, Francesca Ronco, MD1*, D'Errigo Maria Grazia4*, Morabito Fortunato, MD5*, Galimberti Sara, MD6*, Enrico Balleari, MD7*, Giorgina Specchia, MD8*, Agostino Cortelezzi, MD9*, Antonella Poloni, MD10*, Carlo Finelli, MD11*, Giuliana Alimena3*, Pasquale Iacopino, MD2*, Carmelo Laganà, MD4*, Francesco Mendicino, MD12*, Filippo Rodà, MD1* and Francesco Nobile, MD1*

1Hematology, Azienda Ospedaliera (B-M-M), Reggio Calabria, Italy
2Bone Marrow Unit, Azienda Ospedaliera (B-M-M), Reggio Calabria, Italy
3Department of Cellular Biotechnologies and Hematology, University "La Sapienza", Rome, Italy
4Genetics, Azienda Ospedaliera (B-M-M), Reggio Calabria, Italy
5Hematology, Azienda Ospedaliera di Cosenza, Cosenza, Italy
6Dept. of Oncology, Transplants and Advanced Technologies, St. Chiara Hospital, University of Pisa, Pisa, Italy
7Hematology Unit, Ospedale San Martino, Genova, Italy
8Hematology, University of Bari, Bari, Italy
9Hematology Unit, Ospedale Maggiore Policlinico, and University of Milan, Milan, Italy
10Università Politecnica delle Marche, Ancona, Italy
11Hematology and Medical Oncology, University of Bologna, Italy, University of Bologna, Bologna, Italy
12Hematology, A.O. Sant'Andrea, Rome, Italy

POU4F1 Is Associated with t(8;21) AML and Contributes Directly to Its Unique Transcriptional Signature

Julie M. Fortier, PhD1*, Jacqueline E. Payton, MD, PhD2*, Patrick Cahan3*, Timothy J. Ley, MD4, Matthew J. Walter, MD5 and Timothy A. Graubert, MD6

1Dept of Medicine, Div of Oncology, Siteman Cancer Center, Washington Univ. School of Medicine, Saint Louis, MO
2Pathology and Immunology, Washington University School of Medicine, Siteman Cancer Center, Saint Louis, MO
3Dept of Medicine, Div of Oncology, Siteman Cancer Center, Washington University in Saint Louis, School of Medicine, Saint Louis, MO
4Dept of Medicine, Div of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
5Dept of Medicine, Div of Oncology, Siteman Cancer Center, Washington Univ. in St. Louis, Saint Louis, MO
6Dept of Medicine, Div of Oncology, Siteman Cancer Center, Washington University, Saint Louis, MO

Integrated Molecular and Pharmacogenetic Profiles in Prediction of Early Response to Therapy in Children with Acute Lymphoblastic Leukemia (ALL): A Report From Malaysia-Singapore ALL Study Group

Yi Lu, Ph.D.1*, Shirley Kow Yin Kham, B.Sc.1*, Hany Ariffin, M.D.2*, Ah Moy Tan, M.D.3*, Hai Peng Lin, M.D.4*, Thuan Chong Quah, M.D.5* and Allen Eng Juh Yeoh, M.D.5*

1Department of Paediatrics, National University of Singapore, Singapore, Singapore
2Department of Paediatrics, University of Malaya Medical Centre, Kuala Lumpur, Malaysia
3KK Women's and Children's Hospital, Singapore, Singapore
4Department of Haematology, Subang Jaya Medical Center, Selangor Darul Ehsan, Malaysia
5Department of Paediatrics, National University Health System, Singapore, Singapore

Thiopurine Methyltransferase Genetics Is Associated with Treatment Outcome and Hepatic Toxicity in Pediatric Patients with Acute Lymphoblastic Leukemia: a Report From the ALL-BFM Study GroupClinically Relevant Abstract

Martin Stanulla, MD1*, Elke Schäffeler, PhD2*, Silke Pohlschmidt3*, Martin Zimmermann, PhD4*, Anja Möricke, MD5*, Gunnar Cario, MD5*, Andre Schrauder, MD5*, Karl Welte, MD6, Jochen Harbott, PhD7, Wolf-Dieter Ludwig, MD8, Alfred Reiter, MD9, Michel Eichelbaum, MD2*, Martin Schrappe, MD10 and Matthias Schwab, MD2*

1Dpt of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
2Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
3Hannover Medical School, Hannover, Germany
4Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
5Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
6Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany
7Department of Paediatric Haematology/Oncology, Oncogenetic Laboratory, Justus-Liebig-Universität Giessen, Giessen, Germany
8Hematology, Oncology, and Tumor Immunology, Robert-Rossle-Clinic at the HELIOS Klinikum Berlin-Buch, Charité, Berlin, Germany
9Dept. of Pediatric Hematology and Oncology, Children's University Hospital, Giessen, Germany
10Deparment of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

The Prognostic Role of Smac/DIABLO Protein Expression in Acute Myeloid Leukemia

Agnieszka Pluta1*, Agata Wrzesien-Kus1*, Barbara Cebula2*, Anna Wolska1*, Anna Szmigielska-Kaplon1*, Magdalena Czemerska1*, Piotr Smolewski2*, Tadeusz Robak1 and Agnieszka Wierzbowska1*

1Department of Hematology, Medical University of Lodz, Lodz, Poland
2Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland

Correlation of Altered Expression of RIZ1 to Diagnosis, Risk Stratification, and Disease Progression in 56 Acute Leukemia Patients

Qiubai Li, MD1*, Xiaojian Zhu, MD1*, Xiaoqing Li, PhD2*, Xiangjun Chen3*, Yong You, MD1*, Shi Huang4*, Shiang Huang, MD5, Ping Zou, MD1* and Zhichao Chen1*

1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, China
22.Center for Stem Cell Research and Application, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3Center for Stem Cell Research and Application, Union Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, China
4Burnham Institute for Medical Research, La Jolla, CA
5Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, CA, China

Evidence for a Pathological Ratio of CD44s/CD44v6 in Chronic Lymphoctic Leukemia (CLL) Cells

Magdalena Hertweck*, Felix Erdfelder*, Alexandra Filipovich*, Sabrina Uhrmacher*, Rajesh Kumar Gandhirajan*, Iris Gehrke*, Julian Paesler*, Regina Razavi*, Simon Jonas Poll-Wolbeck*, Michael Hallek, MD and Karl Anton Kreuzer, MD*

Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany

Gene Expression Profiling Identifies IGFBP7 as a BAALC Co-Expressed Gene with a Functional Role in Acute LeukemiaClinically Relevant Abstract

Sandra Heesch, MS1*, Cornelia Schlee, MS1*, Martin Neumann1*, Andrea Stroux2*, Andrea Kühnl1*, Stefan Schwartz, Dr.1*, Torsten Haferlach, MD3, Nicola Goekbuget4, Dieter Hoelzer, MD, PhD5, Wolf-Karsten Hofmann6*, Eckhard Thiel, MD, PhD1 and Claudia D Baldus, MD1*

1Hematology, Oncology, Charité, Campus Benjamin Franklin, Berlin, Germany
2Biostatistics and Clinical Epidemiology, Charité Campus Benjamin Franklin, Berlin, Germany
3MLL Munich Leukemia Laboratory, Munich, Germany
4Medical Department II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Germany
5Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital, Frankfurt/M, Germany
6Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany

Acquired Somatic Uniparental Disomy is a Chromosomal Defect Important in Predicting Treatment Responses and Survival Outcomes in MDS, MDS/MPN and Secondary AMLClinically Relevant Abstract

Ramon V. Tiu, MD1, Christine O'Keefe, PhD1*, Lukasz P. Gondek, MD2*, Azim M. Mohamedali, PhD3*, Bartlomiej P. Przychodzen4*, Ghulam J. Mufti, MBBS, DM, FRCP, FRCPath5, Mikkael A. Sekeres, MD, MS6, Anjali S. Advani6, Michael A. McDevitt, MD, PhD7 and Jaroslaw P. Maciejewski, MD, PhD1

1Department of Translational Hematology and Oncology Research, Cleveland Clinic,Taussig Cancer Institute, Cleveland, OH
2Department of Translational Hematology and Oncology Research/ Internal Medicine, Cleveland Clinic, Cleveland, OH
3Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom
4Cleveland Clinic, Cleveland, OH
5Department of Haematological Medicine, King's College London, London, United Kingdom
6Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
7Division of Hematological Malignancy, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

Analysis of the Serum Free Light Chain Ratio and Its Prognostic Value in a Cohort of Patients with Chronic Lymphocytic Leukemia

Chaim Shustik, MD1, Stephen Harding, PhD2*, Keyue Ding3*, Liting Zhu3*, Laura Z. Rassenti, PhD4, Thomas J. Kipps, MD, PhD4, Lois Shepherd, MD5 and Melanie Robson6*

1Royal Victoria Hospital, Montreal, QC, Canada
2Hevylite, The Binding Site Group Ltd, Birmingham, United Kingdom
3Cancer Research Institute, NCIC Clinical Trials Group, Kingston, ON
4Moores UCSD Cancer Center, CLL Research Consortium, La Jolla, CA
5Queen's University, Kingston, ON, Canada
6Birmingham City University, Birmingham, United Kingdom

In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival

Frank G Rücker, M.D.1*, Richard F Schlenk, M.D.1, Lars Bullinger, M.D.1, Helena Kett1*, Annegret Becker1*, Carla-Maria Kugler1*, Thorsten Zenz, MD1*, Peter Lichter, Ph.D.2*, Jürgen Krauter, M.D.3*, Brigitte Schlegelberger, M.D.4, Arnold Ganser, M.D.3, Hartmut Döhner, M.D.1 and Konstanze Döhner, M.D.1*

1Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
2Division Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
3Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
4Institute for Cellular and Molecular Pathology, Hannover Medical School, Hannover, Germany

Clinical Relevance of Ubiquitin-Proteasome System Profiling in Acute Leukemias

Wanlong Ma1*, Hagop M. Kantarjian, MD2, XI Zhang1*, Xiuqiang Wang3*, Zeev Estrov, MD4, Susan O'Brien4* and Maher Albitar, MD1*

1Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
2Leukemia, MD Anderson Cancer Center, Houston, TX
3Quest Diagnostics Nichols Institute, San Juan Capistrano
4Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031:  a Report From the Children’s Oncology Group

Bill H Chang, MD, PhD1, Stephanie G Willis2*, Linda C. Stork, MD3, Stephen P Hunger, MD4, William L. Carroll, MD5, Bruce Camitta, MD6, Naomi J. Winick, MD7, Brian J. Druker, MD1 and Kirk R. Schultz, MD8

1Oregon Health & Science University Knight Cancer Institute, Portland, OR
2Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute, Portland, OR
3OR Health Sciences Univ., Portland, OR
4Pediatric Heme/Onc/BMT, University of Colorado College of Medicine, Aurora, CO
5New York University Cancer Institute, New York, NY
6Medical College of Wisc., Milwaukee, WI
7University of Texas Southwestern Medical Center, Dallas, TX
8B.C. Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada

A New Molecular and Clinical Prognostic Score for Risk Stratification in CN-AML

Friederike Schneider1*, Annika Dufour1*, Tobias Benthaus1*, Stephanie Schneider1*, Gudrun Mellert1*, Evelyn Zellmeier1*, Stefan K Bohlander1*, Michael Unterhalt1*, Michaela Feuring-Buske1*, Christian Buske1*, Jan Braess1*, Maria Cristina Sauerland2*, Achim Heinecke2*, Wolfgang Berdel3, Thomas Buechner3*, Bernhard Wörmann4*, Wolfgang Hiddemann1, Karsten Spiekermann1* and Eva Hoster1*

1Department of Internal Medicine III, University Hospital Munich - Campus Grosshadern, Munich, Germany
2Department of Medical Informatics and Biomathematics, University of Muenster, Muenster, Germany
3Department of Medicine, Hematology and Oncology, University of Muenster, Muenster, Germany
4Department of Hematology and Oncology, Municipal Hospital Braunschweig, Braunschweig, Germany

Polymorphisms of Exon 10 in Stem Cell Factor Receptor KIT Are Associated with a Significantly Improved Relapse-Free Survival in Childhood AML

Muriel Malaise, PhD1*, Juan Du, MD2*, Beate Junk1*, Kerstin Wittke3*, Martin Zimmermann, PhD4*, Dirk Reinhardt, MD, PhD5, Konstanze Doehner, MD2*, Klaus-Michael Debatin, MD6 and Selim Corbacioglu, MD1

1Pediatrics, University of Ulm, Ulm, Germany
2Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
3Internal Medicine III, University of Ulm, Ulm, Germany
4Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
5AML BFM study group, Hannover Medical School, Hannover, Germany
6Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany

Aberrant DNA Methylation in Childhood Acute Lymphoblastic Leukemia as a Potential Biomarker Reflecting Disease Status

Seung Yeon Kwon1*, Sung Chul Won1*, Hyo Sun Kim1*, Hei-Cheul Jeung2*, Sun Young Rha2*, Kyu Hyun Park3*, Jaewoo Song, MD4 and Chuhl Joo Lyu, MD, PhD1*

1Pediatrics, Yonsei University College of Medicine, Seoul, South Korea
2Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
3Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
4Laboratory Medicine, Yonsei University College of Medicine, Seoul, South Korea

AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome

Mahesh Seetharam, MD1, Olga K Weinberg, MD2*, Li Ren, MS3*, Lisa Ma, MS2*, Katie Seo, MS2*, James L. Zehnder, MD1, Jason R Gotlib, MD, MS1* and Daniel A. Arber, MD2

1Hematology, Stanford Cancer Center, Stanford Univ., Stanford, CA
2Pathology, Stanford Univ. Medical Center, Stanford, CA
3Center for Clinical Investigation, Department of Medicine, Stanford Univ. Medical Center, Stanford, CA

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaemia (AML)Clinically Relevant Abstract

James X Gray, MD, PhD*, Lyle McMillen, PhD*, Russell Saal, MMedSc*, Steven Lane, MBBS*, Peter Mollee, MBBS, Robert Bird, MBBS*, Devinder Gill, MBChB* and Paula Marlton, MBBS

Haematology, Princess Alexandra Hospital, Brisbane, Australia

Gene Dosage Effects in B-Chronic Lymphocytic Leukemia with Del 13q14

Ludger Sellmann, MD1*, Rene Scholtysik2*, Holger Nueckel, MD3*, Tanja Boes4*, Alexander Carpinteiro, MD3*, Ulrich Duehrsen, MD1, Ludger Klein-Hitpass2*, Jan Duerig, MD1* and Ralf Kueppers5*

1Department of Hematology, University Hospital Essen, Essen, Germany
2Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany, Essen, Germany
3Department of Hematology, University Hospital of Essen, Essen, Germany
4Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, Essen, Germany, Essen, Germany
5Institute of Cell Biology (Tumor Research), University Duisburg-Essen, Essen, Germany

New LMO2 Translocations in T-Cell Acute Lymphoblastic Leukemia, Involving STAG2 at Xq25 and MBNL1 at 3q25: A Positive Change?

Suning Chen1*, Stefan Nagel2*, Bjoern Schneider3*, Maren Kaufmann2*, Ursula R. Kees4*, Hans G. Drexler5 and Roderick A.F. MacLeod2*

1First Affiliated Hospital of Soochow University, Suzhou, China
2Human and Animal Cell Lines, DSMZ, Braunschweig, Germany
3Human and Animal Cell Cultures, DSMZ - German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany
4Division of Children's Leukaemia and Cancer Research, Telethon Institute for Child Health Research and Centre for Child Health Research, University of Western Australia, Perth, Australia
5DSMZ, Braunschweig, Germany

Low Levels of Global (LINE) and CDH13 Methylation at Diagnosis and Rapid Clearance of Marrow Blasts Correlate with A Better Haematological Response to Azacitidine in Patients with Newly Diagnosed and Refractory/Relapsed AML Not Eligible for or Resistant to Chemotherapy: A Multi-Centre Phase I/II-Study of the East German Haematology and Oncology Study Group (OSHO)

Michael Cross1*, Nadja Jaekel2*, Rainer Krahl3*, Christian Junghanss, MD4*, Georg Maschmeyer5, Thao Tran3*, Gisa Hoppe6*, Dietger Niederwieser, MD7 and Haifa Kathrin Al-Ali, MD2*

1Department of Hematology/Oncology and Hemostasiology, University of Leipzig, Leipzig, Germany
2Hematology/Oncology, University of Leipzig, Leipzig, Germany
3Department of Hematology/Oncology, University of Leipzig, Leipzig, Germany
4Hematology/Oncology, University of Rostock, Rostock, Germany
5Dept. of Hematology/ Oncology, Ernst-von-Bergmann Clinic, Potsdam, Germany
6Celgene GmbH, Muenchen, Germany
7University of Leipzig, Leipzig, Germany

Prevalence and Prognostic Impact of CEBPA mutations in Children with AML Treated with the AIEOP-LAM 2002/01 Protocol

Giovanni Cazzaniga1, Riccardo Masetti2*, Giulia Ferrari1*, Tiziana Coliva1*, Carmelo Rizzari3*, Roberto Rondelli2*, Fiorina Casale4*, Franca Fagioli5*, Luca Lo Nigro6, Matteo Luciani7*, Concetta Micalizzi8*, Giuseppe Menna9*, Maria Caterina Putti10*, Nicola Santoro11*, Giuseppe Basso12*, Franco Locatelli13*, Andrea Biondi1 and Andrea Pession2

1M.Tettamanti Research Center, Pediatric Clinic University of Milan Bicocca, Monza, Italy
2Department of Pediatrics, University of Bologna, Bologna, Italy
3Pediatric Clinic University of Milan Bicocca, Monza, Italy
4University of Naples Federico II, Naples, Italy
5University of Turin, Torino
6Center of Pediatric Hematology Oncology, Azienda Policlinico - University of Catania, Catania, Italy
7Ospedale Bambin Gesù, Rome, Italy
8Ospedale G Gaslini, Genova, Italy
9Departments of Pediatrics, Santobono-Pausilipon Hospital, Naples, Italy
10Pediatric Clinic, University of Padua, Italy
11Azienda Policlinico - Università di Bari, Bari, Italy
12Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy
13Pediatric Hematology/Oncology, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Recurrent Novel Regions of Uniparental Disomy and Homozygous Deletions in Mycosis Fungoides Identified Using High Resolution Single Nucleotide Polymorphism Analysis

Azim M Mohamedali, PhD1*, Tracey J Mitchell, PhD2*, Silvia Ferreira, PhD2*, Barbara A Guinn, PhD3, Robin M. Ireland, FRCP, FRCPath4, Sean J Whittaker, MD, FRCP2* and Ghulam J Mufti, MBBS, DM, FRCP, FRCPath1

1Department of Haematological Medicine, King's College London, London, United Kingdom
2Skin Tumour Unit, St John's Institute of Dermatology, Kings College London & Guy's & St. Thomas's NHS Foundation Trust, London, United Kingdom
3Genetic Vaccine Group (MP 891), Cancer Sciences Division, Southampton, England
4Haematological Medicine, King's College Hospital, London, England

Analysis of the PI3/Akt/Survivin Pathway in Acute Myelogenous Leukemia

Josefina Serrano1*, Juana Serrano-Lopez1*, Joaquin Sanchez Garcia1*, Concepcion Herrera1* and Antonio P. Torres Gomez, MD2

1Hematology, University Hospital Reina Sofia, Cordoba, Spain
2Hematology, Reina Sofia Hospital, Córdoba, Spain

Highly Sensitive Quenching Probe (QProbe) Method Is Useful to Detect c-Kit Mutation and to Predict Relapse of t(8;21)(q22;q22) Acute Myeloid LeukemiaClinically Relevant Abstract

Satoshi Wakita*, Hiroki Yamaguchi, Yoshio Mitamura*, Fumiko Kosaka*, Koiti Inokuchi and Kazuo Dan

Division of Hematology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan

Leukemic T-PLL Cells Exhibit Short and Narrowly Distributed Telomere Lengths and High Telomerase Activities, Associated with Rapid and Dose-Dependent Cell Death Following Telomerase Inhibition by Imetelstat Sodium

Gabriela M. Baerlocher, MD1, Katia Bassett, PhD2*, Dirk de Beer3*, Laurence Elias, MD2, Ning F Go, MD2* and Alexander Roeth, MD4

1Dept. of Hematology, University Hospital and University Bern, Bern, Switzerland
2Geron Corporation, Menlo Park, CA
3Department of Clinical Research, University of Bern, Bern, Switzerland
4Department of Hematology, University Hospital Essen, Essen, Germany

Implications On Drug Resistance and Survival of ABCB1 Single Nucleotide Polymorphisms in Normal Karyotype De Novo AML

Christer Paul, professor1, Henrik Green, PhD2*, Ingrid Jakobsen Falk, B.Sc.2*, Kourosh Lotfi, MD, PhD3*, Esbjorn Paul, MD4*, Monika Hermansson, PhD5*, Richard Rosenquist, professor6, Kerstin Jonsson-Videsater, PhD7* and Hareth Nahi, MD, PhD8*

1Karolinska Institutet, Department of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
2Clinical Pharmacology, Department of Medical and Health Sciences, University of Linkoping, Linkoping, Sweden
3Hematological Clinic, Department of Medical and Health Sciences, University of Linkoping, Linkoping, Sweden
4Department of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
5Department of Genetics and Pathology, Uppsala University, Uppsala, Uppsala, Sweden
6Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
7Department of Hematology, Karolinska Institutet, Stockholm, Sweden
8Karolinska Institutet/Karolinska University Hospital Huddinge, Stockholm, Sweden

Black Patients with Acute Myeloid Leukemia (AML) Are Younger and More Commonly Female, but Have a Higher Incidence of Complex Karyotypes When Compared to Whites

Jason Bierenbaum, MD1*, Yi Ning, Ph.D.2*, Arnold Hoffman3*, Ivana Gojo, MD1 and Maria R Baer, MD1

1Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
2Department of Pathology, University of Maryland School of Medicine, Baltimore, MD
3Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD

Immunological Shift On Day 15 of Remission Induction in Children with CD10-Positive B-Cell Precursor ALL Treated by ALL-MB 2008 Protocol

Alexander Popov, MD1*, Tatiana Verzhbitskaya, MD, PhD2*, Grigory Tsaur, MD, PhD2*, Egor Shorikov, MD, PhD2*, Leonid Saveliev, MD, PhD1* and Larisa Fechina, MD, PhD2

1Chair of Clinical Laboratory Medicine, Ural State Medical Academy, Yekaterinburg, Russia
2Pediatric Oncology and Hematology Center, Regional Children Hospital #1, Research Institute of Medical Cell Technologies, Yekaterinburg, Russia

Synergistic Activity of Co-Treatment with PIM1 Kinase Inhibitor SGI-1776 and Histone Deacetylase Inhibitor Panobinostat or Heat Shock Protein 90 Inhibitor AUY922 against Human CML and Myeloproliferative Neoplasm (MPN) Cells

Warren C. Fiskus1*, Kathleen M. Buckley1*, Rekha Rao1*, Yongchao Wang1*, Atul Joshi1*, Daniel G. Chong1*, Anand Jillella1*, Celalettin Ustun1*, Peter Atajada2*, Cornelia Quadt3* and Kapil N. Bhalla1

1Medical College of Georgia Cancer Center, Augusta, GA
2Novartis Institute for Biomedical Research, Inc, Cambridge, MA
3Early Clinical Development, Novartis Pharma AG, Basel, Switzerland

Risk Stratification Using a New Prognostic Model for Patients with Secondary Acute Myeloid Leukemia - Results of the DSIL-AML96 TrialClinically Relevant Abstract

Friedrich Stölzel1*, Walter E. Aulitzky2, Heinrich Bodenstein3*, Martin Bornhäuser4*, Michael Kramer4*, Brigitte Mohr5*, Uta Oelschlägel5*, Norbert Schmitz6*, Silke Soucek4*, Christian Thiede7*, Gerhard Ehninger4 and Markus Schaich8*

1Medizinische Klinik I, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
2GMMG, Germany, Germany
3Klinik für Hämatologie und Onkologie, Klinikum Minden, Minden, Germany
4Medical Clinic I, University Hospital, Dresden, Germany
5Hematology, University Hospital, Dresden, Germany
6Depatment of Hematology & Stem cell transplantation, Asclepios Clinic St. Georg, Hamburg, Germany
7Internal Medicine I, University Hospital, Dresden, Germany
8Medical Department 1, University Hospital, Dresden, Germany

Single-Cell Phospho-Profiling in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Reveals Signaling Differences in Cytogenetic and Prognostic Subgroups

Manon Queudeville, MD*, Sarah M. Eckhoff, MD*, Klaus-Michael Debatin, MD and Lueder H. Meyer, MD*

Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany

Heterogeneity in Phenotype, Functional Capacity, and Drug Sensitivity for Pediatric Acute Leukemia

Christina M. Wiedl, DO1, Terzah M. Horton, MD, PhD2, Randall M Rossi, M.S.3*, Sarah J Neering, M.S.3*, Valerie Grose, B.S.3* and Craig T. Jordan, PhD3

1Strong Memorial Hospital of the University of Rochester, Rochester, NY
2Baylor College of Medicine, Houston, TX
3James P Wilmot Cancer Center, University of Rochester, Rochester, NY

Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies

Teresa A Bennett, Ph.D.1*, Sandra Sapia, MD, Hematopathologist2*, Daniel Primo, PhD2*, Lilia Suarez, PhD3*, Santiago Lago, PhD3*, Maria Matoses, PhD3*, Ana Espinosa, PhD3*, Consuelo Tudela, PhD3*, Elena Arroyo, PhD3*, Julian Gorrochategui, PhD3*, William C Jackson, PhD3*, Alex Okun, PhD4*, Horacio Hector Lopez, PhD3*, Isolde Gornemann, MD3*, Soledad Gallego Melcon, MD5*, Cristina Diaz de Heredia, MD6*, Jose Luis Dapena, MD7*, Josep M Roma, MD8*, Regina Garcia Delgado, MD9*, Mari Paz Queipodellano, MD9*, Alicia Bailen, MD10*, Manuel Barrios11*, Eva Diez, PhD12*, Santiago Del Castillo, MD, PhD13*, Ana Isabel Heiniger14*, Jose Sanchez de Toledo15*, Manuel Ramirez Sr., MD, PhD16*, Macarena Ortiz, MD17*, Marcos González18*, Jesús F. San-Miguel, MD, PhD19, Enrique M Ocio20*, Andrew G. Bosanquet, PhD, MRCPath21*, Alberto Orfao, MD, PhD22* and Joan Ballesteros, PhD3*

1Vivia Biotech, Malaga, Spain
2Vivia Biotech, SL, Malaga, Spain
3Vivia Biotech SL, Malaga, Spain
4Etogen Inc., San Diego, CA
5Servei d'Oncologia, Vall d Hebron Hospital Materno-Infantil, Barcelona, Spain
6Servei d'Oncologia, Vall dxHebron Hospital Materno-Infantil, Barcelona, Spain
7Vall d Hebron Hospital Materno-Infantil, Barcelona, Spain
8Vall dxHebron Hospital Materno-Infantil, Barcelona, Spain
9Hospital Universitario Virgen de la Victoria, Malaga, Spain
10Hospital Carlos Haya, Malaga, Spain
11Hematology, Carlos Haya Hospital, Málaga, Spain
12Hospital Universitario de Salamanca, Salamanca, Spain
13Hospital Virgen de la Victoria, Malaga, Spain
14Hematology, Carlos Haya Hospital, Malaga, Spain
15Hospital Vall de Hebron, Barcelona, Spain
16Oncohematologia y Trasplante, Hospital Infantil Universitario Nino Jesus, Madrid, Spain
17Hospital Regional Universitario Carlos Haya, Malaga, Spain
18Hematology, HOSPITAL UNIVERSITARIO, SALAMANCA, SPAIN., Salamanca, Spain
19Po. San Vicente, 58-182, Hospital Clinico Universitario de Salamanca, Salamanca, Spain
20Centro de Investigación del Cáncer. IBMCC/CSIC, University of Salamanca, Salamanca, Spain
21Bath Cancer Research,, Bath, England
22Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC); Servicio General de Citometría, Universidad de Salamanca, Salamanca, Spain

Targeting Levels, Aberrant Localization or Oligomerization of Mutant Nucleophosmin Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1

Ramesh Balusu1*, Warren C. Fiskus1*, Rekha Rao1*, Kathleen M. Buckley1*, Yongchao Wang1*, Atul Joshi1*, Sanjay Koul1*, Anand Jillella1*, Celalettin Ustun1*, Susan Sunay2*, H. Jean Khoury2 and Kapil N. Bhalla1

1Medical College of Georgia Cancer Center, Augusta, GA
2Winship Cancer Institute, Emory University, Atlanta, GA

Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML)

Kristen M O'Dwyer, M.D.1*, David Shum, M.S.2*, Mark Heaney, MD, PhD3*, Renier J. Brentjens, MD, PhD4, Peter Maslak, MD5, Joseph G Jurcic, MD6, Hakim Djaballah, Ph.D.2* and Mark G. Frattini, MD, PhD7

1Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
2Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY
3Molecular Pharmacology and Chemistry, MSKCC, New york, NY
4Departement of Medicine and Center of Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
5Memorial Sloan-Kettering Cancer Ctr., New York, NY
6Memorial Sloan-Kettering Cancer Center, New York, NY
7Division of Hem./Onc., Leukemia Service, New York, NY

Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance

Pamela S. Becker, MD, PhD1, Sylvia Chien1*, Mikhail Roshal, MD, PhD2*, Brent Wood, MD, PhD3, Elihu Estey, MD4*, Thalia Papayannopoulou, MD4, Xin Zhao, MD1*, Soumit Basu, MD, PhD1*, Mark McGrath1*, Kenneth Kopecky, PhD5* and Frederick R Appelbaum, MD6

1Division of Hematology, University of Washington, Seattle, WA
2Laboratory Medicine, University of Washington, Seattle, WA
3Department of Laboratory Medicine, University of Washington, Seattle, WA
4University of Washington, Seattle, WA
5Southwest Oncology Group, Fred Hutchinson Cancer Research Center, Seattle, WA
6Fred Hutchinson Cancer Research Center & U. of Washington, Seattle, WA

*signifies non-member of ASH